NCT07258836 2026-04-17
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
Eli Lilly and Company
Phase 1 Recruiting
Clinical Trials
994 trialsNCT06959706 2026-04-16
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Tagworks Pharmaceuticals BV
Phase 1 Recruiting
NCT01481532 2026-04-15
Open Label Clinical Trial of Intravenous Crotoxin Part 3
Celtic Biotech Ltd
Phase 1 Not yet recruiting
NCT06803680 2026-04-15
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07532018 2026-04-15
DXP-106
Singlomics (Beijing DanXu) Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT04958239 2026-04-14
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT05382559 2026-04-14
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT06150157 2026-04-14
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT04606381 2026-04-13
PALOMA
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06178614 2026-04-13
A Study of JNJ-87890387 for Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07247110 2026-04-13
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT07524140 2026-04-13
Study of ZE94-0605 in Patients With Advanced Solid Tumors, With Dose Expansion Cohorts.
Eilean Therapeutics
Phase 1 Not yet recruiting
NCT07525141 2026-04-13
A Study of JNJ-1761981 in Participants With Solid Tumors
Johnson & Johnson Enterprise Innovation Inc.
Phase 1 Not yet recruiting
NCT06555744 2026-04-09
A Study of ZW191 in Participants With Solid Tumors
Zymeworks BC Inc.
Phase 1 Recruiting
NCT06997029 2026-04-07
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT07438782 2026-04-06
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Recruiting
NCT07455617 2026-04-06
Study of ABO2102 in KRAS-Mutated Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
Phase 1 Recruiting
NCT04050709 2026-04-01
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
ImmunityBio, Inc.
Phase 1 Completed
NCT03449381 2026-03-31
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Completed
NCT06188208 2026-03-30
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Vividion Therapeutics, Inc.
Phase 1 Terminated
NCT06884618 2026-03-30
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
Hoffmann-La Roche
Phase 1 Recruiting
NCT04419532 2026-03-20
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Phase 1 Active not recruiting
NCT05720117 2026-03-20
A Study of PYX-201 in Advanced Solid Tumors
Pyxis Oncology, Inc
Phase 1 Recruiting
NCT07403721 2026-03-19
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Amgen
Phase 1 Recruiting
NCT04443088 2026-03-18
KEYNOTE-E12
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1 Recruiting
NCT05719558 2026-03-18
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT06540066 2026-03-16
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT07030712 2026-03-16
MK-8294-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT05935098 2026-03-13
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT05557045 2026-03-12
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT06713369 2026-03-04
AZD5305
AstraZeneca
Phase 1 Recruiting
NCT03391778 2026-03-03
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
USWM, LLC (dba US WorldMeds)
Phase 1 Recruiting
NCT07046559 2026-03-03
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants
Eli Lilly and Company
Phase 1 Recruiting
NCT06759649 2026-02-27
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
Compugen Ltd
Phase 1 Recruiting
NCT06521554 2026-02-25
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Nuvalent Inc.
Phase 1 Recruiting
NCT07156136 2026-02-25
Study of IMC-P115C in Advanced PRAME-Positive Cancers
Immunocore Ltd
Phase 1 Recruiting
NCT00750841 2026-02-23
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
NCT05396833 2026-02-19
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
EMD Serono
Phase 1 Active not recruiting
NCT03964233 2026-02-18
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Boehringer Ingelheim
Phase 1 Completed
NCT05365581 2026-02-13
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Astellas Pharma Inc
Phase 1 Recruiting
NCT06311578 2026-02-13
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Johnson & Johnson Enterprise Innovation Inc.
Phase 1 Recruiting
NCT06607939 2026-02-10
OR2-01
Orionis Biosciences Inc
Phase 1 Recruiting
NCT06717750 2026-02-02
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Phase 1 Recruiting
NCT04170153 2026-01-30
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
EMD Serono
Phase 1 Active not recruiting
NCT02952248 2026-01-27
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT07368127 2026-01-26
A Study of TPD3310 in Patients With Advanced Malignant Tumors
TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.
Phase 1 Not yet recruiting
NCT05914545 2026-01-22
A Study of FZ-AD004 in Patients With Advanced Solid Tumors
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT04471987 2026-01-14
DODEKA
Philogen S.p.A.
Phase 1 Recruiting
NCT07292038 2026-01-14
Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors
NucMito Pharmaceuticals Co. Ltd.
Phase 1 Recruiting
NCT06235437 2026-01-07
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141
Ascendo Biotechnology Co., Ltd.
Phase 1 Recruiting